Recent advances in the knowledge of the pathophysiology of portal hypertens
ion has opened new indications for the pharmacologic treatment of acute var
iceal bleeding. Treatment with vasoactive agents is immediately available,
easy to use and can be considered as definitive or adjunctive to endoscopic
therapy. The data from randomised trials of vasoactive drug treatment for
acute variceal bleeding are reviewed, using meta-analysis where applicable.
The use of vasopressin has been decreased as a consequence of its question
able efficacy and its high incidence of side effects. Terlipressin is the o
nly drug that has been shown to improve survival, albeit in small trials an
d there are insufficient data of its use over 5 days. Somatostatin has been
shown to have similar efficacy with terlipressin with significantly less s
ide effects. The demonstrated efficacy of octreotide in acute variceal blee
ding is less than terlipressin and somatostatin and it cannot be considered
as drug of fi rst choice. Somatostatin combined with sclerotherapy represe
nts the optimal therapy today as this combination has been shown to be more
effective than sclerotherapy alone and it is safe given over 5 days. Copyr
ight (C) 1999 S. Karger AG, Basel.